Work

Engineering a TME-responsive hollow ZnzMnx-zOy-based nanoplatform for cancer theranostic applications

Year: 2025
Type: article
Abstract: This study engineered a tumor microenvironment (TME)-responsive theranostic nanosystem by employing hollow zinc-doped manganese oxide (H-Zn z Mn x-z O y ) nanostructures. Doping Zn 2+ ions into the Mn x O y matrix induces lattice distortion, increases microstrain, and improves surface heterogeneity, thereby enhancing drug-loading capacity and catalytic performance. Meanwhile, optimization of the nanoplatform at Z = 0.05 yielded a high specific surface area (S BET = 49.11 m 2 g −1 ) and a mesoporous structure. Furthermore, the surface was modified using chitosan cross-linked with tripolyphosphate (Chi-TPP) to enhance biocompatibility and colloidal stability under physiological conditions. Adsorption studies revealed a maximum PTX loading capacity of 151.069 mg g −1 under the optimal conditions (160 ppm PTX, 0.9 mg mL −1 nanoplatform, and 7 h contact time), with a loading efficiency of 89.7 %. The in vitro release studies demonstrated that PTX release was highly selective under tumor-mimicking conditions, including acidic pH, elevated temperature, 100 μM H 2 O 2 , and 10 mM glutathione (GSH), resulting in 86 % drug release. In contrast, less than 10 % release occurred under normal physiological conditions, confirming the TME-specific responsiveness of the nanoplatform. Moreover, in phantom experiments using T 1 -weighted magnetic resonance imaging (MRI), the longitudinal relaxivity ( r 1 ) increased15-fold (7.74 vs. 0.52 mM −1 s −1 ) under simulated TME conditions, which was attributed to the release of Mn 2+ ions via catalytic degradation. Cytotoxicity assays indicated that non-specific cell toxicity was markedly reduced by Chi-TPP surface modification while retaining efficient PTX delivery capability. Collectively, the H-Zn z Mn x-z O y @Chi-TPP@PTX nanosystem serves as a multifunctional platform for TME-responsive hypoxia modulation and MRI bioimaging, enabling targeted drug delivery (TDD) and controlled release.
Language: English
Open Access status: gold
Estimated APC paid: $1,300
OpenAlex ID: W4415753491
FWCI:
Cites: 88
Cited by:
Related to: